With over 200 biosimilars approved globally (1) and many top-selling biologics losing exclusivity in the next five years, the demand for cost-efficient, large-scale production of recombinant antibody therapeutics is growing.
Signal peptides in biosimilar development: Small sequences, big impact
With over 200 biosimilars approved globally (1) and many top-selling biologics losing exclusivity in the next five years, the demand for cost-efficient, large-scale production of recombinant antibody therapeutics is growing.
Reviewing real-life success stories: How signal peptide engineering can boost mRNA therapy development
Strong evidence exists for applying signal peptide engineering to design more efficient vaccines for various infectious viral diseases, including Ebola virus, SARS-Cov-2, and Zika virus.
The virus innovates – why aren’t we? Rethinking signal peptides in biologics development
While viruses tirelessly reinvent themselves to optimize infection and immune evasion, including refining their signal peptides to optimize viral replication in the secretory pathway, the ability to engineer viral signal peptides for biotechnology tends to remain limited.
Understanding signal peptides: Small expression elements and their therapeutic implications
This blog sheds light on the significant role of signal peptides in protein synthesis and therapy development.
Using signal peptides to enhance expression of de novo-designed proteins
In this blog, we examine how signal peptide engineering can address challenges in the expression of de novo-designed proteins.
Leveraging signal peptides for smarter mRNA design
Advances in high throughput signal peptide analysis and computational models are creating new possibilities for smarter mRNA design.